Claims for Patent: 12,616,740

Summary for Patent: 12,616,740

Title:	Methods of using a GIP/GLP1 co-agonist for therapy
Abstract:	The present invention provides a method for increasing glycemic control in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. The present invention provides a method for improving weight management in a patient in need thereof, by administering tirzepatide, or a pharmaceutically acceptable salt thereof. Further providing a method for treating a condition selected from atherosclerosis, chronic kidney disease, NAFLD, and NASH. Further provided is a method to prevent or induce remission of diabetes comprising administration of tirzepatide, or a pharmaceutically acceptable salt thereof. Further provided is a dosing regimen for increasing glycemic control, improving weight management, and/or treating dyslipidemia.
Inventor(s):	Charles T. BENSON, Axel Haupt, Melissa Kay THOMAS, Shweta URVA
Assignee:	Eli Lilly and Co
Application Number:	US19/217,808
Patent Claims:	1. A method for treating type 2 diabetes in a patient comprising: administering to the patient tirzepatide in once-weekly doses, the administering comprising: administering a first once-weekly dose of 2.5 mg for four weeks; increasing the once-weekly dose by increments of 2.5 mg to a once weekly maintenance dose of 5, 10, or 15 mg, wherein each increased once weekly dose is administered for at least four weeks; and administering the maintenance dose of 5, 10, or 15 mg once weekly to treat type 2 diabetes in the patient, wherein the patient has type 2 diabetes and the tirzepatide is administered subcutaneously to the patient. 2. The method of claim 1, further comprising administering metformin to the patient. 3. The method of claim 1, wherein the maintenance dose is 5 mg. 4. The method of claim 1, wherein the maintenance dose is 10 mg. 5. The method of claim 1, wherein the maintenance dose is 15 mg. 6. A method for treating obesity in a patient comprising; administering to the patient tirzepatide in once-weekly doses, the administering comprising: administering a first once-weekly dose of 2.5 mg for four weeks; increasing the once-weekly dose by increments of 2.5 mg to a once weekly maintenance dose of 5, 10, or 15 mg, wherein each increased once weekly dose is administered for at least four weeks; and administering the maintenance dose of 5, 10, or 15 mg once weekly to treat obesity in the patient, wherein the tirzepatide is administered subcutaneously to the patient. 7. The method of claim 6, further comprising administering metformin to the patient. 8. The method of claim 6, wherein the maintenance dose is 5 mg. 9. The method of claim 6, wherein the maintenance dose is 10 mg. 10. The method of claim 6, wherein the maintenance dose is 15 mg. 11. A method for improving glycemic control in a patient with type 2 diabetes, comprising: administering tirzepatide at a dosage of 2.5 mg once weekly for at least four weeks, and increasing the dosage to 5 mg once weekly, wherein tirzepatide is administered by subcutaneous injection. 12. The method of claim 11, further comprising increasing the dosage to 7.5 mg once weekly after at least four weeks at 5 mg once weekly. 13. The method of claim 12, further comprising increasing the dosage to 10 mg once weekly after at least four weeks at 7.5 mg once weekly. 14. The method of claim 13, further comprising increasing the dosage to 12.5 mg once weekly after at least four weeks at 10 mg once weekly. 15. The method of claim 14, further comprising increasing the dosage to 15 mg once weekly after at least four weeks at 12.5 mg once weekly. 16. A method for treating obesity in a patient, comprising administering tirzepatide at a dosage of 2.5 mg once weekly for at least four weeks, and increasing the dosage to 5 mg once weekly, wherein tirzepatide is administered by subcutaneous injection. 17. The method of claim 16, further comprising increasing the dosage to 7.5 mg once weekly after at least four weeks at 5 mg once weekly. 18. The method of claim 17, further comprising increasing the dosage to 10 mg once weekly after at least four weeks at 7.5 mg once weekly. 19. The method of claim 18, further comprising increasing the dosage to 12.5 mg once weekly after at least four weeks at 10 mg once weekly. 20. The method of claim 19, further comprising increasing the dosage to 15 mg once weekly after at least four weeks at 12.5 mg once weekly.